Takeda Pharmaceutical (NYSE:TAK) Sets New 12-Month Low at $13.08

Takeda Pharmaceutical Company Limited (NYSE:TAKGet Free Report) shares hit a new 52-week low on Thursday . The stock traded as low as $13.08 and last traded at $13.11, with a volume of 294162 shares trading hands. The stock had previously closed at $13.23.

Takeda Pharmaceutical Price Performance

The company has a market capitalization of $41.25 billion, a P/E ratio of 19.75, a price-to-earnings-growth ratio of 2.98 and a beta of 0.53. The company’s 50-day moving average price is $14.06 and its two-hundred day moving average price is $14.20. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.06 and a quick ratio of 0.55.

Takeda Pharmaceutical (NYSE:TAKGet Free Report) last issued its quarterly earnings data on Thursday, February 1st. The company reported $0.51 earnings per share for the quarter. Takeda Pharmaceutical had a net margin of 6.90% and a return on equity of 12.57%. The company had revenue of $7.52 billion for the quarter. As a group, sell-side analysts expect that Takeda Pharmaceutical Company Limited will post 1.5 EPS for the current year.

Hedge Funds Weigh In On Takeda Pharmaceutical

Institutional investors and hedge funds have recently modified their holdings of the business. Rise Advisors LLC acquired a new position in shares of Takeda Pharmaceutical in the first quarter valued at about $26,000. GAMMA Investing LLC acquired a new stake in Takeda Pharmaceutical during the fourth quarter worth about $28,000. Principal Securities Inc. acquired a new stake in Takeda Pharmaceutical during the fourth quarter worth about $28,000. First United Bank & Trust acquired a new stake in Takeda Pharmaceutical during the fourth quarter worth about $29,000. Finally, Lindbrook Capital LLC grew its stake in Takeda Pharmaceutical by 40.6% during the fourth quarter. Lindbrook Capital LLC now owns 4,065 shares of the company’s stock worth $58,000 after buying an additional 1,174 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Company Profile

(Get Free Report)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

Further Reading

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.